Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Bristol-Myers checks in big time in lung cancer
Company: Bristol-Myers Squibb (NYSE:BMY)
Therapy: Nivolumab and ipilimumab
Disease: Non-small cell lung cancer (NSCLC)
News: BMY announced findings from the CheckMate-227 study, which is assessing (in part) the combination of nivolumab and ipilimumab compared with chemotherapy in previously untreated NSCLC. The study has met one of its primary endpoints, progression-free survival, in patients with so-called high tumor mutational burden, assessed using a Foundation Medicine (NASDAQ:FMI) assay. The study will continue to follow patients to assess overall survival.
Looking forward: You'd better go ahead and start getting used to hearing "tumor mutational burden" when it comes to immunotherapies, because it's quickly emerged as one of the most promising biomarkers of response to the immune checkpoint inhibitors. Likely, this is also BMY's first salvo to finally getting nivolumab approved in first-line lung, although the toxicity is still a potential issue here.
Overall, this is great news for BMY, and it puts Merck (NYSE:MRK) in its sights.
Amgen stumbles in bone care study
Company: Amgen (NASDAQ:AMGN)
Disease: Bone complications relating to breast cancer
News: AMGN's partner announced top line findings from the D-CARE study, which assessed the RANKL inhibitor denosumab compared with placebo as adjuvant therapy for early-stage breast cancer at a high risk of recurrence. Unfortunately, the study did not meet its primary endpoint of bone metastasis-free survival. The findings will be presented in full at a later date.
Looking forward: This is definitely a setback for the continued growth of the denosumab franchise, which currently brings in billions in revenue for AMGN. So certainly, this news isn't catastrophic for AMGN, but now it's at a greater risk for erosion of sales as biosimilars are explored.
As patent expirations loom in the coming years, AMGN is going to need to look for innovation in other areas.
EyeGate comes crashing down after trial failure
Company: EyeGate (NASDAQ:EYEG)
Disease: Post-cataract surgery inflammation and pain
News: EYEG announced top line findings from its phase 2b study involving EGP-437 in patients who have undergone cataract surgery. Although there were trends towards improvements in the study endpoints, the co-primary endpoints were not significantly improved. The company explained that the vehicle control appeared to perform better than anticipated, making its as-expected efficacy end up in trial failure.
Looking forward: Unfortunately, this is the reality of clinical trials when you're operating on relatively fine lines of improvement for patients. The drug performed as expected, but it cannot be determined that it had a genuine effect because of better-than-expected performance of the control.
If EYEG can't get a response squared away quickly, then it's likely its time is up. I would be hyper-cautious about investing in the stock at this time.
Author's note: Thank you for taking some time out of your day to read some commentary on recent biotech happenings. I hope you'll consider leaving a comment or a question in the section below! This is one way in which Seeking Alpha is able to gauge the effectiveness of its writers and the platform. So if you want to keep seeing more editions of "3 Things," go ahead and participate!
As I mentioned above, I am now collaborating with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively or in advance. I will also collaborate in developing watchlists and other investment essentials. Please subscribe to TPT by clicking on this link - Total Pharma Tracker.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article covers one or more microcap stocks. Please be aware of the risks associated with these stocks.